keytruda keep drive train
good enough result guidanc backdrop sever
peer report surpris downsid
somewhat surpris extent initi posit reaction merck
share surpris investor would see merck good name
go forward expect keytruda continu key driver
upsid focu move beyond line lung cancer opportun
product gain traction adjuv melanoma line renal cell
carcinoma rcc also continu roll-out outsid us
adjuv melanoma expect fda approv feb
action date feb also see strong surviv data
keytruda combin pfe inlyta rcc asco-gu
notabl model updat follow quarter updat model
account compani guidanc increas near mid-term
 expens assumpt modestli lower assumpt around
gross margin sg ep estim slightli lower
lower result next sever year pleas let us know
would like updat excel-bas model compani
valuat risk ep estim
maintain target
price outperform rate tp blend dcf
rel valuat dcf base cash flow forecast
along termin growth rate discount rate
rel valuat base ep blue sky
valuat grey sky valuat main risk
bullish view merck disappoint clinic data especi keytruda
and/or poor commerci execut especi keytruda gardasil
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
merck co inc global health care compani deliv health
solut prescript medicin market
joint ventur oper segment
anim health consum allianc
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
keytruda bridion gardasil compar current base case
assumpt also model higher gross margin oper
margin base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
keytruda bridion gardasil compar current base case
assumpt also model lower gross margin oper
margin base assumpt grey sky valuat base
dcf driven wacc termin valu
 close
proquad m-m-r ii varivax
sale
share
currenc impact revenu
currenc impact ep
low mid-singl digit low mid-singl digit
acquisition- divestiture-rel cost
decreas increas net incom
revenu
amort intang
equiti incom affili
total incom expens
provis incom tax
proquad m-m-r ii varivax
primari women
hospit specialti
charl martineau pm univers toronto compani mention price
